FDA has expanded the indication of Lynparza (olaparib) to include its combination with bevacizumab for first-line maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Researchers at the University of California, Los Angeles found that a first-line combination of atezolizumab, an immunotherapy drug that boosts the body's natural defenses, and bevacizumab, an anti-angiogenesis drug that inhibits the growth of tumors' blood vessels, significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer.
Five studies from the virtual scientific program of the 2020 American Society of Clinical Oncology Annual Meeting were highlighted in a press briefing and released May 13:
Mary Ann LongLaurie J. SmithTimothy QuinnThree leaders were appointed to Roswell Park Comprehensive Cancer Center:
Science Health Education Center at Dana-Farber Cancer Institute launched the SHE Biobank initiative, a large, long-term study that will investigate the impact of genetic predisposition and environmental exposure to the development of disease
Sophie Paczesny and Shikhar Mehrotra were named co-leaders of the cancer immunology program at Hollings Cancer Center at the Medical University of South Carolina.
Two component institutions of Heartland Cancer Research NCORP have created drive-through laboratory services for outpatients during the COVID-19 crisis.
An immunotherapy combination, rintatolimod and interferon alfa, first evaluated at Roswell Park Comprehensive Cancer Center as an approach for treating some solid tumor cancers will soon be available to cancer patients with COVID-19 through a clinical trial at Roswell Park.
Researchers from MSK Kids at Memorial Sloan Kettering Cancer Center found that children with cancer are not at a higher risk of being affected by COVID-19.
GRYT Health and Bristol Myers Squibb Co. developed the COVID Advocacy Exchange, a virtual platform to connect patient advocacy organizations, patients, policy makers, healthcare practitioners, and industry in the exchange of information.
